10-K: Mainz Biomed pivots, plans massive recap

Mainz Biomed slashes legacy cancer programs, sells ColoAlert IP, lines up $6M preferred financing that could exceed 95% dilution, and seeks shareholder approval to rebrand as Quantum Cyber N.V.

Summary

• Shift in strategy: discontinued ColoAlert and next‑gen CRC programs in Feb 2026; sold ColoAlert IP on Mar 28, 2026 for a $348,966 note reduction (remaining $300,000 payable).
• Focus going forward: develop a blood-based pancreatic cancer screening test under a March 2025 Liquid Biosciences license (total $1.2M fee in installments through May 1, 2026); early discovery cohorts reported 95% sensitivity and 98% specificity (not yet product-validated).
• Expansion plan: pursue post‑quantum cybersecurity; propose name change to Quantum Cyber N.V. and already trading as QUCY.
• Capital: on Feb 13, 2026, entered a $6M preferred investment with David Lazar—$3M closed (Series A–C) and $3M prepaid in Mar 2026 (Series D–E), fully convertible upon shareholder approval to >95% of fully diluted shares.
• Extraordinary Shareholders’ Meeting set for Apr 22, 2026 to approve preferred conversions, large authorized share increase, reverse split (1:2 to 1:100), board appointments, auditor, plan amendments, and name change.
• Nasdaq notice on Mar 20, 2026 for minimum bid deficiency; 180‑day cure period to Sep 16, 2026; reverse split authority on the agenda.
• 2025 results: revenue $537,080 (-40% YoY); gross margin 73% (vs 64%); net loss $(16.21)M (vs $(21.60)M); operating cash outflow $(10.98)M; government grants $0.53M; intangible impairment $2.64M.
• Liquidity: cash $889,091 at Dec 31, 2025; working capital deficit ~$1.9M; substantial doubt about going concern; raised $2.09M via ATM in Jan 2026 and $3M preferred in Feb 2026 (plus $3M prepaid for second closing).
• Governance/controls: material weaknesses in ICFR; ceased to be a foreign private issuer on Jan 1, 2026 and converted reporting to U.S. GAAP.
• Workforce: ~10 full-time and 3 part-time employees as of Mar 30, 2026; terminations tied to CRC wind‑down scheduled Feb–May 2026; aggregate ~$1.9M settlement obligations to officers/directors and ~$0.8M severance to employees upon final closing.

Sentiment

Score: 3

Explanation: StockSavvy.ai views the filing as materially negative due to revenue decline, going concern risks, potential extreme dilution/change of control, and listing deficiency—partially offset by cost reductions and near‑term funding.

Positives

• Clear cost actions: 2025 operating expenses down 15% to $16.53M; net loss narrowed by 25% to $(16.21)M.
• Gross margin improvement to 73% (from 64%) after shifting away from lower‑margin DTC operations.
• Non-dilutive support: $533,503 of government grants recognized in 2025.
• Pancreatic program secured: $1.2M license for biomarkers/AI algorithm; discovery cohorts showed 95% sensitivity and 98% specificity (subject to replication in a product setting).
• Near-term funding runway: $3M preferred first closing in Feb 2026 plus $3M prepaid for second closing; $2.09M raised via ATM in Jan 2026.

Negatives

• Revenue contraction: 2025 revenue $537,080, down 40% year over year.
• Going concern warning: cash $889,091, working capital deficit ~$1.9M, and operating cash burn $(10.98)M in 2025.
• Severe dilution/control shift likely: preferred conversions (Series A–E) would exceed 95% of fully diluted shares post‑approval.
• Nasdaq listing risk: received minimum bid price deficiency on Mar 20, 2026; cure deadline Sep 16, 2026; reverse split likely.
• Intangible impairment: $2,640,280 charge in 2025 tied to CRC IP and wind‑down.
• Material weaknesses in internal controls over financial reporting; disclosure controls not effective as of Dec 31, 2025.
• Business pivot risk: exiting core CRC franchise; pivot to post‑quantum cybersecurity is outside historical domain.

Risks

• Inability to secure required shareholder approvals for preferred conversions and share capital changes, which could derail financing plans and governance reshaping.
• Nasdaq delisting risk due to sub‑$1.00 bid price; failure to regain compliance by Sep 16, 2026 may trigger delisting.
• Substantial doubt about ability to continue as a going concern given limited cash and ongoing losses.
• Execution risk in developing a pancreatic screening product; promising discovery metrics may not replicate in a commercial test.
• Material weaknesses in internal control over financial reporting and ineffective disclosure controls as of year‑end 2025.
• Dependence on strategic shift to post‑quantum cybersecurity without established operating history in that sector.
• Settlement and severance obligations (~$2.7M combined) upon final closing increase near‑term cash needs.
• Customer concentration risk: a few customers represented the majority of 2025 revenue and receivables.

Future Outlook

Near term priorities are to secure shareholder approvals on Apr 22, 2026 for preferred share conversions, capital structure changes, and reverse split; finalize the $3M Second Closing; progress the pancreatic cancer blood-test program under the Liquid Biosciences license; dispose of next‑gen CRC IP; and regain Nasdaq bid‑price compliance within the cure window.

Management Comments

• Refocused resources on the development of a blood-based pancreatic cancer screening product while discontinuing the CRC programs due to funding constraints.
• Board changes and the proposed name change to Quantum Cyber N.V. are intended to align the strategy with expansion into post‑quantum cybersecurity alongside diagnostics.
• Plan to remediate material weaknesses in internal controls during the first half of 2026 and beyond.

Industry Context

StockSavvy.ai notes the pivot leaves the company exiting mainstream CRC screening—dominated by Exact Sciences (Cologuard) and others—to pursue a higher-risk pancreatic screening opportunity where few validated, non‑invasive options exist. Simultaneously, the move into post‑quantum cybersecurity is a major adjacency shift, increasing execution risk relative to diagnostics peers while offering optionality in a rapidly evolving security market.

Comparison to Industry Standards

• Scale and losses: 2025 revenue of ~$0.54M and net loss of ~$16.2M are far below established diagnostics peers (e.g., Exact Sciences, Guardant Health) and consistent with pre‑revenue biotech profiles.
• Clinical positioning: Reported discovery‑stage pancreatic sensitivity/specificity (95%/98%) is high versus typical early biomarker screens but must be replicated in larger, prospective studies to meet regulatory and clinical adoption standards.
• Listing status: Nasdaq minimum‑bid deficiency and reliance on reverse splits are more common among microcaps; larger diagnostics peers generally maintain compliant share prices without such measures.
• Governance/controls: Material ICFR weaknesses contrast with best‑in‑class peers that maintain robust SOX-compliant controls.

Management Changes

Corporate Governance

Legal Proceedings

• Boustead Securities LLC matter: Company filed complaint (Mar 22, 2024); Boustead withdrew arbitration after stay (Sep 12, 2024); Boustead moved to dismiss Company’s claims but has not filed counterclaims; management does not expect a material impact.

Related Party Transactions

• Sale of European Oncology Lab (EOL) business in St. Ingbert, Germany to a related party in 2024 for €31,511.
• Royalty and associated costs paid to ColoAlert AS/Uni Targeting Research AS (related party).
• Intellectual Property Asset Purchase Agreement with Uni Targeting Research AS (related party) for ColoAlert IP (Feb 15, 2023).
• Sale of ColoAlert IP and assets to Uni Targeting Research AS on Mar 28, 2026 for a $348,966 note reduction and $300,000 cash.
• Preferred share investment by David Lazar (appointed director at first closing on Feb 13, 2026): $3M first closing and $3M prepaid second closing, subject to shareholder approvals.

Stakeholder Impact

• Shareholders: significant dilution/change of control risk if preferred conversions are approved; potential reverse split; increased authorized shares.
• Employees: terminations tied to CRC wind‑down between Feb–May 2026; ~$0.8M severance.
• Officers/Directors: aggregate ~$1.9M settlement obligations payable upon final closing.
• Customers/Lab partners: discontinuation of ColoAlert and next‑gen CRC may disrupt prior relationships; focus shifts to pancreatic product.
• Creditors: UTR note reduced by $348,966 through ColoAlert asset sale; additional obligations under settlement agreements.

Next Steps

• Hold Extraordinary Shareholders’ Meeting on Apr 22, 2026 to approve preferred conversions, reverse split, name change, authorized share increases, auditor, and director slate.
• Complete the $3M Second Closing of preferred shares post‑approval and implement board/management transitions.
• Continue development of the pancreatic cancer blood‑based test and complete remaining license payment by May 1, 2026.
• Market and complete the sale of next‑gen CRC intellectual property.
• Implement internal control remediation measures targeted for the first half of 2026.
• Address Nasdaq bid price compliance, including potential reverse split execution.

Key Dates

Recommendation

The combination of a 40% revenue decline, going concern uncertainty, Nasdaq bid-price deficiency, material control weaknesses, and a financing structure that could result in >95% dilution/change of control suggests unfavorable risk-reward for shareholders despite cost cuts and a potentially promising pancreatic program. Until approvals, financing certainty, and operational traction are demonstrated, risk-aware investors would likely reduce exposure.

Keywords

Mainz Biomed, Quantum Cyber N.V., pancreatic cancer screening, Liquid Biosciences, post-quantum cybersecurity, preferred shares, David Lazar, Nasdaq minimum bid price, reverse stock split, ColoAlert sale, going concern, internal control weakness, Equity Distribution Agreement, shareholder meeting, authorized share increase